葛兰素史克Q3业绩超预期，上调全年核心每股收益增长指引

老虎资讯综合

Oct 29

10月29日，葛兰素史克美股夜盘涨近3%！第三季度业绩超预期，上调全年核心每股收益增长指引。

财报显示，第三季度营收85.5亿英镑，预估82.8亿英镑；三季度经调整后每股收益55便士，预估47便士。

专科药品销售额34亿英镑（增长16%）；呼吸系统、免疫和炎症类药品10亿英镑（增长15%）；肿瘤类药品5亿英镑（增长39%）；HIV类药品销售额19亿英镑（增长12%）；
疫苗销售额27亿英镑（增长2%）；带状疱疹疫苗（Shingrix）8亿英镑（增长13%）；脑膜炎疫苗5亿英镑（增长5%）；以及阿瑞维疫苗（Arexvy）3亿英镑（增长36%）；
普通药品销售额25亿英镑（增长4%）； Trelegy 营收 7 亿英镑（+25%）

总营业利润和每股收益均增长超过 100%，主要得益于重大法律费用降低、CCL 费用降低以及其他营业收入增加，部分被无形资产减值所抵消。

核心营业利润增长 11%，核心每股收益增长 14%，反映了专科药物和疫苗业务的增长、更高的特许权使用费收入，以及在肿瘤和疫苗研发组合推进方面持续增加的投资。

经营活动产生的现金流为 25 亿英镑，自由现金流为 12 亿英镑。

葛兰素史克将全年核心每股收益增长指引上调至10%到12%；预计全年营收增长6%-7%；预计全年销售额按固定汇率计算增长6%至7%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1105822524"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105822524\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105822524?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2025-10-29 15:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105822524","market":"us","top_or_hot":-1,"title":"葛兰素史克Q3业绩超预期，上调全年核心每股收益增长指引","media":"老虎资讯综合","content":"<html><head></head><body><p>10月29日，<a href=\"https://laohu8.com/S/GSK\">葛兰素史克</a>美股夜盘涨近3%！第三季度业绩超预期，上调全年核心每股收益增长指引。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dbc1585dbb260431a43e3bf6a22fed90\" title=\"\" tg-width=\"837\" tg-height=\"831\"/></p><p style=\"text-align: start;\">财报显示，第三季度营收85.5亿英镑，预估82.8亿英镑；三季度经调整后每股收益55便士，预估47便士。</p><ul style=\"\"><li><p>专科药品销售额34亿英镑（增长16%）；呼吸系统、免疫和炎症类药品10亿英镑（增长15%）；肿瘤类药品5亿英镑（增长39%）；HIV类药品销售额19亿英镑（增长12%）；</p></li><li><p>疫苗销售额27亿英镑（增长2%）；带状疱疹疫苗（Shingrix）8亿英镑（增长13%）；脑膜炎疫苗5亿英镑（增长5%）；以及阿瑞维疫苗（Arexvy）3亿英镑（增长36%）；</p></li><li><p>普通药品销售额25亿英镑（增长4%）； Trelegy 营收 7 亿英镑（+25%）</p></li></ul><p>总营业利润和每股收益均增长超过 100%，主要得益于重大法律费用降低、CCL 费用降低以及其他营业收入增加，部分被无形资产减值所抵消。</p><p>核心营业利润增长 11%，核心每股收益增长 14%，反映了专科药物和疫苗业务的增长、更高的特许权使用费收入，以及在肿瘤和疫苗研发组合推进方面持续增加的投资。</p><p>经营活动产生的现金流为 25 亿英镑，自由现金流为 12 亿英镑。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a0c86373931a4ce3c968aaf13cd77dee\" title=\"\" tg-width=\"945\" tg-height=\"708\"/></p><p style=\"text-align: start;\">葛兰素史克将全年核心每股收益增长指引上调至10%到12%；预计全年营收增长6%-7%；预计全年销售额按固定汇率计算增长6%至7%。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>葛兰素史克Q3业绩超预期，上调全年核心每股收益增长指引</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n葛兰素史克Q3业绩超预期，上调全年核心每股收益增长指引\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-10-29 15:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>10月29日，<a href=\"https://laohu8.com/S/GSK\">葛兰素史克</a>美股夜盘涨近3%！第三季度业绩超预期，上调全年核心每股收益增长指引。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dbc1585dbb260431a43e3bf6a22fed90\" title=\"\" tg-width=\"837\" tg-height=\"831\"/></p><p style=\"text-align: start;\">财报显示，第三季度营收85.5亿英镑，预估82.8亿英镑；三季度经调整后每股收益55便士，预估47便士。</p><ul style=\"\"><li><p>专科药品销售额34亿英镑（增长16%）；呼吸系统、免疫和炎症类药品10亿英镑（增长15%）；肿瘤类药品5亿英镑（增长39%）；HIV类药品销售额19亿英镑（增长12%）；</p></li><li><p>疫苗销售额27亿英镑（增长2%）；带状疱疹疫苗（Shingrix）8亿英镑（增长13%）；脑膜炎疫苗5亿英镑（增长5%）；以及阿瑞维疫苗（Arexvy）3亿英镑（增长36%）；</p></li><li><p>普通药品销售额25亿英镑（增长4%）； Trelegy 营收 7 亿英镑（+25%）</p></li></ul><p>总营业利润和每股收益均增长超过 100%，主要得益于重大法律费用降低、CCL 费用降低以及其他营业收入增加，部分被无形资产减值所抵消。</p><p>核心营业利润增长 11%，核心每股收益增长 14%，反映了专科药物和疫苗业务的增长、更高的特许权使用费收入，以及在肿瘤和疫苗研发组合推进方面持续增加的投资。</p><p>经营活动产生的现金流为 25 亿英镑，自由现金流为 12 亿英镑。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a0c86373931a4ce3c968aaf13cd77dee\" title=\"\" tg-width=\"945\" tg-height=\"708\"/></p><p style=\"text-align: start;\">葛兰素史克将全年核心每股收益增长指引上调至10%到12%；预计全年营收增长6%-7%；预计全年销售额按固定汇率计算增长6%至7%。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK.UK","symbol_name":"葛兰素史克","start_time":0,"source_url":"","article_id":"1105822524","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105822524","pubTimestamp":1761721745,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"10月29日，$葛兰素史克(GSK)$美股夜盘涨近3%！第三季度业绩超预期，上调全年核心每股收益增长指引。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"GSK.UK":"葛兰素史克","GSK":"葛兰素史克"},"translate_title":"GlaxoSmithKline's Q3 results exceed expectations, raises full-year core EPS growth guidance","themeId":"ef522f117157951d640983c1fa6537a4","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/51a304cd0206c146f9331ba2ced3ef3e","symbols_score_info":{"GSK":1,"GSK.UK":0.6},"content_text":"10月29日，葛兰素史克美股夜盘涨近3%！第三季度业绩超预期，上调全年核心每股收益增长指引。财报显示，第三季度营收85.5亿英镑，预估82.8亿英镑；三季度经调整后每股收益55便士，预估47便士。专科药品销售额34亿英镑（增长16%）；呼吸系统、免疫和炎症类药品10亿英镑（增长15%）；肿瘤类药品5亿英镑（增长39%）；HIV类药品销售额19亿英镑（增长12%）；疫苗销售额27亿英镑（增长2%）；带状疱疹疫苗（Shingrix）8亿英镑（增长13%）；脑膜炎疫苗5亿英镑（增长5%）；以及阿瑞维疫苗（Arexvy）3亿英镑（增长36%）；普通药品销售额25亿英镑（增长4%）； Trelegy 营收 7 亿英镑（+25%）总营业利润和每股收益均增长超过 100%，主要得益于重大法律费用降低、CCL 费用降低以及其他营业收入增加，部分被无形资产减值所抵消。核心营业利润增长 11%，核心每股收益增长 14%，反映了专科药物和疫苗业务的增长、更高的特许权使用费收入，以及在肿瘤和疫苗研发组合推进方面持续增加的投资。经营活动产生的现金流为 25 亿英镑，自由现金流为 12 亿英镑。葛兰素史克将全年核心每股收益增长指引上调至10%到12%；预计全年营收增长6%-7%；预计全年销售额按固定汇率计算增长6%至7%。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}